Symbol="INKT"
AssetType="Common Stock"
Name="Mink Therapeutics Inc"
Description="MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York."
CIK="1840229"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="62992000"
EBITDA="-29288728"
PERatio="None"
PEGRatio="None"
BookValue="-0.13"
DividendPerShare="0"
DividendYield="0"
EPS="-0.81"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.698"
ReturnOnEquityTTM="-4.037"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.81"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="8.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="11.5"
EVToRevenue="-"
EVToEBITDA="-3.702"
Beta="None"
num_52WeekHigh="4.32"
num_52WeekLow="0.851"
num_50DayMovingAverage="2.053"
num_200DayMovingAverage="2.155"
SharesOutstanding="34422100"
DividendDate="None"
ExDividendDate="None"
symbol="INKT"
open="1.83"
high="1.85"
low="1.72"
price="1.76"
volume="59881.00"
latest_trading_day="2023-07-24"
previous_close="1.83"
change="-0.07"
change_percent="-3.8251%"
aroon_positive_momentum_days="42"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="42"
Volume_recent_avg="130945"
Change_recent_avg="-0.02"
Delta_recent_avg="0.21"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-1.71"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="42"
Aroon_momentum_negative="58"
image_negative_thumbnail_id_1="106"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0070.jpeg"
image_negative_thumbnail_id_2="1120"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0153.jpeg"
image_neutral_thumbnail_id_1="571"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0028.jpeg"
image_neutral_thumbnail_id_2="554"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0045.jpeg"
image_positive_thumbnail_id_1="952"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0114.jpeg"
image_positive_thumbnail_id_2="649"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0059.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1189"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
